The estimated Net Worth of Dong Kim is at least $367 ezer dollars as of 31 January 2024. Dong Kim owns over 3,333 units of UroGen Pharma Ltd stock worth over $367,139 and over the last 3 years Dong sold URGN stock worth over $0.
Dong has made over 1 trades of the UroGen Pharma Ltd stock since 2024, according to the Form 4 filled with the SEC. Most recently Dong exercised 3,333 units of URGN stock worth $46,029 on 31 January 2024.
The largest trade Dong's ever made was exercising 3,333 units of UroGen Pharma Ltd stock on 31 January 2024 worth over $46,029. On average, Dong trades about 833 units every 0 days since 2022. As of 31 January 2024 Dong still owns at least 26,585 units of UroGen Pharma Ltd stock.
You can see the complete history of Dong Kim stock trades at the bottom of the page.
Dong's mailing address filed with the SEC is 400 ALEXANDER PARK DRIVE, , PRINCETON, NJ, 08540.
Over the last 7 years, insiders at UroGen Pharma Ltd have traded over $8,740,363 worth of UroGen Pharma Ltd stock and bought 33,940 units worth $791,524 . The most active insiders traders include Ran Nussbaum, Arie Belldegrun és Kathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of $214,027. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth $138,100.
urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.
UroGen Pharma Ltd executives and other stock owners filed with the SEC include: